Abstract: A display panel and a display device are provided. The display panel includes a display area and at least two non-display areas arranged adjacently along a first direction. The display area at least partially surrounds the non-display areas. Each non-display area includes at least one light-transmitting area and a wiring area, and the wiring area at least partially surrounds the at least one light-transmitting area. The display area includes pixel circuits and driving signal lines electrically connected with the pixel circuits. A driving signal line includes a first segment in the display area, a first connection line located in the wiring area, and a second segment located between the at least two non-display areas that are arranged adjacently. The first segment is connected to the second segment through the first connection line and the first segment is at least located at a side of the at least two non-display areas that are arranged adjacently.

Abstract: An MRI contrast agent, including superparamagnetic nanoparticles and hydroxyethyl starch. The weight ratio of the superparamagnetic nanoparticles to the hydroxyethyl starch is between 1:5 and 1:15. The superparamagnetic nanoparticles have a particle size of 100-140 nm, and include the following layers, from the inside out, ferrous ferric oxide particles, citric acid, and poly-R-lysine. The citric acid accounts for 6-13 wt. % of the ferrous ferric oxide particles. The poly-R-lysine accounts for 6-20 wt. % of the ferrous ferric oxide particles.

Abstract: The invention provides the Zidovudine-conjugated quinoline compound N-((1-(2-(hydroxy-methyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-tetrahydrofuran-3-yl)-1H-1,2,3-triazol-4-yl)methyl)-6-(4b,8,8-trimethyl-4b,5,6,7,8,8a-hexahydrodibenzo[a,c]phenazin-2-yloxy)hexanamide. The compound can selectively kill hepatoma cells, especially hepatoma cells with hepatitis B, and inhibit the growth of subcutaneous tumors in mice, but has no significant toxicity to normal liver cells. Experiments confirm that the compound has an anti-hepatoma effect and can be used in preparation of anti-hepatoma drugs.

Abstract: The invention provides Zidovudine conjugated quinoline compound N-((1-(2-(Hydroxy-methyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-tetrahydrofuran-3-yl)-1H-1,2,3-triazol-4-yl)methyl)-6-(4b,8,8-trimethyl-4b,5,6,7,8,8a-hexahydrodibenzo[a,c]phenazin-2-yloxy)hexanamide. The compound can selectively kills the hepatoma cells especially the hepatoma cells with hepatitis B, and inhibit the growth of subcutaneous tumors in mice, but has no significant toxicity to normal liver cells. Experiments confirm the compound has anti-hepatoma effect, and can be used in preparation of anti-hepatoma drugs.

Abstract: 4b,5,6,7,8,8a-cis-hexahydro-2-hydroxy-4b,8,8a-trimethylphenanthren-9,10-dione (OHCT) is a fully oxidized compound based on the 2-hydroxy-cis-terpenone (HCT). Because OHCT is fully oxidized, it is more stable and less likely to damage cells or cell constituents such as DNA. OHCT has antimalarial activity, noncompetitive inhibitory activity against carcinogenic conversion of aflotoxin B1 (AFB1) to exo-AFB1-epoxide thus inihibiting AFB1 induced cellular toxicity, and inhibitory activity against TCDD induced cellular toxicity.

Abstract: The present invention relates to selective, target-activated modification of target molecules. The present invention also relates to methods and reagents for the selective, target-activated modification of target molecules. The present invention further relates to intermediates in the selective, target-activated modification of target molecules.